Louisiana State Employees Retirement System Raises Position in United Therapeutics Corporation $UTHR

Louisiana State Employees Retirement System grew its position in United Therapeutics Corporation (NASDAQ:UTHR) by 1.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 12,700 shares of the biotechnology company’s stock after buying an additional 200 shares during the period. Louisiana State Employees Retirement System’s holdings in United Therapeutics were worth $3,649,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics during the second quarter valued at approximately $29,000. SVB Wealth LLC purchased a new position in shares of United Therapeutics during the first quarter valued at approximately $32,000. Geneos Wealth Management Inc. raised its holdings in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Sound Income Strategies LLC purchased a new position in shares of United Therapeutics during the first quarter valued at approximately $49,000. Finally, Brooklyn Investment Group raised its holdings in shares of United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 98 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $11,356,133.75. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 257,935 shares of company stock valued at $103,782,672. Company insiders own 10.30% of the company’s stock.

United Therapeutics Trading Down 1.7%

Shares of NASDAQ UTHR opened at $448.93 on Thursday. The firm has a market capitalization of $20.25 billion, a price-to-earnings ratio of 17.52, a price-to-earnings-growth ratio of 6.96 and a beta of 0.66. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $459.48. The firm has a 50 day moving average of $365.94 and a 200 day moving average of $321.87.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.85 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of United Therapeutics in a report on Friday, September 26th. They set an “outperform” rating and a $569.00 price objective for the company. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $295.00 to $414.00 and gave the company an “equal weight” rating in a report on Wednesday, September 3rd. Weiss Ratings reissued a “hold (c+)” rating on shares of United Therapeutics in a report on Wednesday. UBS Group boosted their target price on shares of United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research report on Monday, September 29th. Finally, Bank of America boosted their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Ten investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $449.57.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.